ABBVIE’s MAVIRET™ approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes.

ABBVIE’s MAVIRET™ approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes.

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that Health Canada has granted approval for MAVIRET™ (glecaprevir/pibrentasvir tablets), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). read more